ArticleWellcome open research2026
Breastmilk transfer of cabotegravir and infant safety outcomes in mothers on cabotegravir for HIV prevention in Lilongwe, Malawi: A protocol for an observational pharmacokinetic study, CABMILK Study.
Article in Wellcome open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Long-Acting Injectable Antiretroviral Therapies for HIV Treatment and Prevention: Clinical Pharmacology, Recent Advances and Future Opportunities.Journal of clinical pharmacology · 2026Review
- Breastmilk transfer of cabotegravir and infant safety outcomes in mothers on cabotegravir for HIV prevention in Lilongwe, Malawi: A protocol for an observational pharmacokinetic study, CABMILK Study.Wellcome open research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Background: Long-acting injectable cabotegravir (CAB-LA) is highly effective for HIV pre-exposure prophylaxis (PrEP). However, lactating women have been underrepresented in pharmacokinetic and safety studies despite their elevated risk of HIV acquisition and potential postnatal transmission through breastfeeding. Data on cabotegravir transfer into breast milk and infant exposure remain limited. The Cabotegravir in Mother-Infant Pairs and Lactation Pharmacokinetics (CABMILK) study addresses this evidence gap to inform safe and equitable PrEP delivery within maternal and child health services in Malawi. Objectives: The primary objective is to quantify cabotegravir transfer into breast milk and estimate infant exposure following maternal use of CAB-LA for PrEP. Secondary objectives are to describe and contextualise infant safety outcomes, including growth, developmental status, and adverse events-among infants whose mothers receive CAB-LA, oral PrEP (tenofovir disoproxil fumarate/emtricitabine), or no PrEP, and to explore maternal factors associated with breast milk drug concentrations. Methods: CABMILK is an observational pharmacokinetic study nested within two ongoing CAB-LA implementation studies in Malawi. A total of 100 mother-infant pairs will be enrolled: 25 receiving CAB-LA, 25 receiving oral PrEP, and 50 PrEP-naïve. Serial maternal plasma and breast milk samples will be collected to quantify cabotegravir concentrations using validated LC-MS/MS assays and to estimate milk-to-plasma ratios and infant exposure. Infant safety monitoring will include clinical assessments, growth measurements, and developmental evaluation using the Caregiver Reported Early Development Index (CREDI) Short Form over 8 months of follow-up. Expected findings: This study will provide empirical data on cabotegravir transfer into breast milk, quantify infant exposure, and generate early comparative safety data. Conclusions: CABMILK will generate essential evidence to guide the safe implementation of CAB-LA among breastfeeding women and inform HIV prevention policy in high-burden settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.